Accéder au contenu
Merck
Toutes les photos(3)

Documents

FCMAB115F

Sigma-Aldrich

Anti-TRA-1-60 Antibody, clone TRA-1-60, FITC conjugate

clone TRA-1-60, from mouse, FITC conjugate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(3)

About This Item

Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

100

Conjugué

FITC conjugate

Forme d'anticorps

purified antibody

Type de produit anticorps

primary antibodies

Clone

TRA-1-60, monoclonal

Réactivité de l'espèce (prédite par homologie)

human (based on 100% sequence homology)

Technique(s)

flow cytometry: suitable
immunocytochemistry: suitable

Isotype

IgM

Conditions d'expédition

wet ice

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... PODXL(5420)

Description générale

Human embryonal carcinoma (EC) cells are the stem cells of teratocarcinomas, and they are key components of germ cell tumors (GCTs). They express several high molecular weight glycoprotein antigens that are down-regulated upon differentiation. One of these antigens, defined by monoclonal antibody TRA-1-60, can be detected in the serum of GCT patients and provides a useful complement to the established serum markers human chorionic gonadotropin and α-fetoprotein, especially in those patients without elevated serum human chorionic gonadotropin or α-fetoprotein.

Spécificité

This antibody reacts with TRA-1-60 antigen that is expressed upon the surface of human tetracarcinoma stem cells (EC), human embryonic germ cells (EG) and human embryonic stem cells (ES).
No immunoreactivity is seen with murine EC, EG, or ES cells. Both the TRA-1-60 and TRA-1-81 monoclonal antibodies (MAB4381) recognize antigens that are associated with a pericellular matrix proteoglycan. TRA-1-60 reacts with a sialidase-sensitive epitope whilst TRA-1-81 reacts with an unknown epitope of the same molecule

Immunogène

- Whole Cells corresponding to the of TRA-1-60.

Application

Detect TRA-1-60 using this Anti-TRA-1-60 Antibody, clone TRA-1-60, FITC conjugate validated for use in FC & IC.
Immunocytochemical staining of fixed H9 human ES cells incubated for two hours at 2-8C with 1:100 dilution of anti-TRA-1-60 FITC conjugated (Cat. No. FCMAB115F) monoclonal antibody. Pluripotent human ES cells exhibit strong immunoreactivity to this antibody.
Immunocytochemical staining of live H9 human ES cells incubated for 30 minutes at 37C with 1:100 dilution of anti-TRA-1-60 FITC conjugated (Cat. No. FCMAB115F) monoclonal antibody. Pluripotent human ES cells exhibit strong immunoreactivity to this antibody.
Flow Cytometry:
Antibody dilution for cellular staining:
  • Prepare an antibody working solution by diluting 1:5 the primary antibody with PBS.
  • Dispense the volume per test of working of solution according to the number of cells indicated in the table below.
  • 5 L for Guava Flow Cytometer
  • 10 L for other Flow Cytometry instruments

5 μl Working Solution: 5 x 105 Cells / 95 μl PBS. 100 μl Total Reaction Volume
10 μl Working Solution: 1 x 106 Cells / 90 μl PBS. 100 μl Total Reaction Volume
Research Category
Stem Cell Research
Research Sub Category
Pluripotent & Early Differentiation

Description de la cible

~235/410 kDa

Forme physique

Purified mouse monoclonal IgM conjugated to FITC in PBS with less than 0.09% sodium azide and 15 mg/mL BSA.

Stockage et stabilité

Maintain refrigerated at 2-8ºC protected from light in undiluted aliquots for up to 6 months from date of receipt.

Remarque sur l'analyse

Control
Pluripotent human embryonic stem (ES) cells

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Cathelijn E M Aarts et al.
Stem cell research, 54, 102444-102444 (2021-06-29)
Induced pluripotent stem cells (iPSCs) were generated from blood outgrowth endothelial cells (BOECs) obtained from a healthy donor and from a patient diagnosed with Hermansky Pudlak Syndrome type 2 (HPS2), caused by compound heterozygous AP3B1 mutations (c.177delA and c.1839-1842delTAGA). BOECs
Chunbo Yang et al.
Human molecular genetics, 26(16), 3031-3045 (2017-05-19)
Hypoplastic left heart syndrome (HLHS) is among the most severe forms of congenital heart disease. Although the consensus view is that reduced flow through the left heart during development is a key factor in the development of the condition, the
Toshio Miki et al.
Stem cell research & therapy, 7, 8-8 (2016-01-14)
Amnion-derived stem cells have been proposed for cell replacement therapy and tissue regeneration. An easily accessible cell source, the placenta, allows us to potentially establish a bio-bank of cells for immunotype matched clinical applications. Several xeno-free (XF) cryopreservation media are
Irina Neganova et al.
Scientific reports, 7, 41693-41693 (2017-02-06)
Reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) holds enormous promise for regenerative medicine. Reprogramming is a stepwise process with well-defined stages of initiation, maturation and stabilisation which are critically dependent on interactions between key pluripotency transcription factors
Robert J Ihry et al.
Nature medicine, 24(7), 939-946 (2018-06-13)
CRISPR/Cas9 has revolutionized our ability to engineer genomes and conduct genome-wide screens in human cells1-3. Whereas some cell types are amenable to genome engineering, genomes of human pluripotent stem cells (hPSCs) have been difficult to engineer, with reduced efficiencies relative
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique